Diagnostics of Cerebral Gliomas With Radiolabeled Amino Acids

被引:16
作者
Langen, K. [1 ]
Tatsch, K. [2 ]
Grosu, A. [3 ]
Jacobs, A. H. [4 ,5 ]
Weckesser, M. [6 ]
Sabri, O. [7 ]
机构
[1] Forschungszentrum Julich, Inst Neurowissensch & Biophys, D-52425 Julich, Germany
[2] Univ Munich, Nukl Med Klin & Poliklin, D-80539 Munich, Germany
[3] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Strahlentherapie & Radiol Onkol, D-8000 Munich, Germany
[4] Max Planck Inst Neurol Res, D-50931 Cologne, Germany
[5] Klinikum Fulda, Klin Neurol & Neurophysiol, Cologne, Germany
[6] Univ Klinikum Munster, Nukl Med Klin & Poliklin, Munster, Germany
[7] Univ Leipzig, Nukl Med Klin & Poliklin, Leipzig, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2008年 / 105卷 / 04期
关键词
amino acid; brain tumors; nuclear medicine; PET; SPECT;
D O I
10.3238/arztebl.2008.0055
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Magnetic resonance tomography (MRT) is the investigation of choice for diagnosing cerebral glioma, but its capacity to differentiate tumor tissue from non-specific tissue changes is limited. Positron emission tomography (PET) and single photon emission computerized tomography (SPECT) using radiolabeled amino acids add information which helps increase diagnostic accuracy. Methods: Review based on the authors' own research results and a selective literature review. Results: The use of radiolabeled amino acids allows better delineation of tumor margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumor recurrence from non-specific post-therapeutic scar tissue, in predicting prognosis in low grade gliomas, and in monitoring metabolic response during treatment. Discussion: The benefits of amino acid imaging in cerebral gliomas support arguments for its introduction into routine clinical practice in defined clinical situations; however, its influence on treatment quality remains to be demonstrated. Dtsch Arztebl Int 2008; 105(4): 55-61 DOI: 10.3238/arztebl.2008.0055
引用
收藏
页码:55 / U2
页数:9
相关论文
共 81 条
[41]   3-[123I]iodo-α-methyl-L-tyrosine:: uptake mechanisms and clinical applications [J].
Langen, KJ ;
Pauleit, D ;
Coenen, HH .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (06) :625-631
[42]   O-(2-[18F]fluoroethyl)-L-tyrosine:: uptake mechanisms and clinical applications [J].
Langen, KJ ;
Hamacher, K ;
Weckesser, M ;
Floeth, F ;
Stoffels, G ;
Bauer, D ;
Coenen, HH ;
Pauleit, D .
NUCLEAR MEDICINE AND BIOLOGY, 2006, 33 (03) :287-294
[43]   Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas [J].
Langen, KJ ;
Jarosch, M ;
Mühlensiepen, H ;
Hamacher, K ;
Bröer, S ;
Jansen, P ;
Zilles, K ;
Coenen, HH .
NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (05) :501-508
[44]  
Leeds Norman E., 1994, Current Opinion in Oncology, V6, P254, DOI 10.1097/00001622-199405000-00006
[45]   Metabolic imaging to follow stereotactic radiation of gliomas -: the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT [J].
Lichy, MP ;
Henze, M ;
Plathow, C ;
Bachert, P ;
Kauczor, HU ;
Schlemmer, HP .
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2004, 176 (08) :1114-1121
[46]   Multimodal target point assessment for stereotactic biopsy with diffuse bithalamic in children astrocytomas [J].
Messing-Jünger, AM ;
Floeth, FW ;
Pauleit, D ;
Reifenberger, G ;
Willing, R ;
Gärtner, J ;
Coenen, HH ;
Langen, KJ .
CHILDS NERVOUS SYSTEM, 2002, 18 (08) :445-449
[47]   Monitoring tumor activity in low grade glioma of childhood [J].
Molenkamp, G ;
Riemann, B ;
Kuwert, T ;
Strater, R ;
Kurlemann, G ;
Schober, O ;
Jurgens, H ;
Wolff, JEA .
KLINISCHE PADIATRIE, 1998, 210 (04) :239-242
[48]  
Moser E, 1997, NUKLEARMED, V36, pB3
[49]  
MOSSKIN M, 1989, ACTA RADIOL, V30, P225
[50]  
MOSSKIN M, 1987, ACTA RADIOL, V28, P673